Sunday, April 17
P2.068 Teriflunomide Mechanism of Action: Linking Species’ Sensitivities to Pregnancy Outcomes —Lynn Davenport,
Andrea Edling, Patrick Finn, Philippe Truffinet, Steve Cavalier
P2.069 Real-World Safety and Efficacy
of Natalizumab After Switching from Other Disease-Modifying Therapies (DMTs): Data from the Tysabri® Observational Program (TOP) —Helmut
Butzkueven, Ludwig Kappos, Maria Trojano, Heinz Wiendl, Radhika Patel, Harold Koendgen, Cynthia Carrillo-Infante, Yi Chen, Pei-Ran Ho, Nolan Campbell
P2.070 Safety of Teriflunomide
in Multiple Sclerosis Treatment. Management of Hepatic Disorders in Real World Experience —Jose E Meca-Lallana, Rocío Hernández-Clares, Ester CarreónGuarnizo, María Cerdan-Sanchez, Cristina Sánchez-Vizcaíno Buendía, Judith JimenezVeiga, Gema Salgado-Cecilia, Adelaida LeonHernández, Jose Javier Martín-Fernández
P2.071 Altered Objective Exertion
Tolerance in MS Patients Treated with Fingolimod: A Prospective, Longitudinal Ergospirometry Study —Christoph Mayer, Hanna Schnitzbauer, Christine Schuhmann, Ulf Ziemann
P2.072 Fingolimod Suppresses Bone
Resorption in Patients with Multiple Sclerosis —Yusei Miyazaki, Masaaki Niino,
Ippei Kanazawa, Masako Suzuki, Masanori Mizuno, Shin Hisahara, Toshiyuki Fukazawa, Eri Takahashi, Itaru Amino, Ryutaro Ochi, Naoya Minami, Naoto Fujiki, Shizuki Doi, Seiji Kikuchi
P2.073 Natalizumab
Associated Progressive Multifocal Leukoencephalopathy: Successful Treatment Without Plasmaexchange and Its Associated Risks —Eimer Maloney, Anna Molloy, Mariam Al Hussona, Luke O'Donnell, Ronan Killeen, Christopher McGuigan
P2.077 4 Years Safety of
Fingolimod in Real World: PANGAEA, a Non-Interventional Study of Safety, Effectiveness and Pharmacoeconomic Data for Fingolimod Patients in Daily Clinical Practice —Tjalf Ziemssen, Holger
Albrecht, Judith Haas, Luisa Klotz, Michael Lang, Chrstoph Lassek, Stephan Schmidt, Bjorn Tackenberg, Christian Cornelissen
P2.078 Dimethyl Fumarate (DMF)-
Induced Necrotizing Myopathy: A Case Report —Charlotte Zisman, Emiliya
Melkumova, Jin Li
P2.079 Rebound Syndrome in Multiple Sclerosis Patients After Cessation of Fingolimod —Stacy Hatcher, Emmanuelle
Waubant, Bardia Nourbakhsh, Elizabeth Crabtree-Hartman, Jennifer Graves
P2.080 Effect of Siponimod Treatment on Vaccination-Induced Immune Response: A Randomized, Double-Blind, Placebo-Controlled Study —Mike Ufer,
Kiran Dole, Jude Ngang, Anne Gardin, Zhenzhong Su, Swathi Peteri, Kasra ShakeriNejad, Eric Legangneux
P2.082 Longterm Fingolimod
Treatment of Multiple Sclerosis Induces Phenotypical Immunsenescence —Nicole Schwanitz, Andreas Boldt, Muriel Stoppe, Johannes Orthgiess, Stefan Borte, Ulrich Sack, Florian Then Bergh
P2.083 Experience with Serious
Fingolimod in Patients with RRMS Receiving Concomitant SSRIs on Day 1: Pooled Analysis of the Real-World PREFERMS and EPOC Studies —Bruce
Hughes, Mark Cascione, Edward Fox, Xiangyi Meng, Brandon Brown
P2.091 Cytomegalovirus Reactivation During Alemtuzumab Treatment for Multiple Sclerosis: A Case Report —
P2.086 Incidence and Timing of
P2.076 Cardiac Safety Profile of the
Jeffrey Cohen, Edward Fox, Hans-Peter Hartung, Eva Havrdova, Krzysztof Selmaj, David Margolin, Linda Kasten, Alasdair Coles
Thyroid Adverse Events in Patients with RRMS Treated with Alemtuzumab Through 5 Years of the CARE-MS Studies —Peter Senior, Douglas Arnold,
P2.087 Immunogenicity with Repeated Dosing of Ocrelizumab in Patients with Multiple Sclerosis —An Song, Robert
Hendricks, Shan Chung, Qing Wang, Peter Chin, Hideki Garren
P2.088 Is Aging and
Immunosenescence a Risk Factor For Dimethyl Fumarate Induced PML? —John Foley, Angelene Christensen, Tamara Hoyt, Angela Foley, Ryan Metzger
48 2016 AAN Annual Meeting Abstract Listing
P2.101 Longitudinal Data on
Lymphopenia in Multiple Sclerosis Patients Treated with Dimethyl Fumarate —Meghan Romba, Annette Wundes, Gloria Von Geldern
P2.102 A Longitudinal Study of JC
Virus Serostatus Stability Among Multiple Sclerosis Patients —Raed Alroughani,
P2.103 Fatal Autoimmune Hemolytic
Selective S1P Receptor Modulator, Ozanimod, from Phase 2 Trials in Relapsing Multiple Sclerosis (RADIANCE) and Moderate to Severe Ulcerative Colitis (TOUCHSTONE) —Paul Frohna, Allan Olson, Matthew Cravets, Jeffrey Hartung, Heather Smith, Richard Aranda, Sheila Gujrathi
in an MS Patient on Fingolimod —Rebecca Straus Farber, Elina Zakin, Aaron Miller
Fingolimod in a Multiple Sclerosis Patient with Prior Immunosuppression —Tirisham Gyang, Johanna Hamel, Andrew Goodman, Lawrence Samkoff
P2.095 Case Report: Atypical
Presentation of PML in a Patient with Alcoholic Cirrhosis —Nassima Baba-
Spicher, Sandra Thiel, Renate KlaaßenMielke, Katja Brandau, Ralf Gold, Kerstin Hellwig
of Prior VZV/HZV Infection in MS: A Survey Study with Serological Validation Sub-Study —Cris Constantinescu, Ali
Valentina Stefanova, Violaine Harris, Saud Sadiq
P2.092 Clinical Safety of the Novel,
P2.084 Disease Course in Elderly MS Bayer, Gabriel Bsteh, Michael Auer, Franziska Di Pauli, Harald Hegen, Thomas Berger
Bone Marrow Mesenchymal Stem CellDerived Neural Progenitors (MSC-NPs) from Patients with Multiple Sclerosis Prior to Intrathecal Injection —Tamara Vyshkina,
Saeed Akhtar, Samar Ahmed, Jasem AlHashel
Ahmed, Robert Neel
Patients —Florian Deisenhammer, Felix
P2.100 Quality Control of Autologous
Stefania De Mercanti, Luca Durelli, Marco Iudicello, Carlo Alberto Artusi, Pierangelo Barbero, Angelo Guerrasio, Marinella Clerico
Cutaneous Events in the DECIDE Study — Corey Ford, Bhupendra Khatri, Tomas Olsson, Tjalf Ziemssen, Xiaojun You, Wanda CastroBorrero, Peter McCroskery
Leukoencephalopathy in the Setting of Idiopathic CD4 Lymphocytopenia: Case Report and Literature Review of the Epidemiology —Tareq Yaqub, Talal Derani,
Gustavo Seifer, Fernando Caceres, Marcela Parada Marcilla, Vladimiro Sinay, Miguel Jacobo, Roberto Rey, Maria Saladino, Andres Villa, Marcos Burgos, Norma Deri, Rossana Neme, Graciela Arguello De Alday, Jose Maria Blasco, Patricio Labal, Christian Calvo Vildoso, Santiago Vetere, Gabriel Volman, Carlos Ballario, Jorge Blanche, Marcelo Matiazzi, Alberto Rodriguez Alfici, Herrera Gustavo, Ramiro Linares, Virginia Laura Parisi, Andres Barboza, Pedro Nofal, Margarita Moreno, Albornoz Liliana, Gaston Kuperman, Andres Greco
P2.090 First-Dose Effects of
P2.094 PML-IRIS Associated with
Manouchehrinia, Radu Tanasescu, Huner Kareem, Oltita Jerca, William Irving
First Dose Observation. Interim Analysis of the Argentinean Registry of Patients Treated with Fingolimod (REAL Study) —
George Dresser, Sarah Morrow
Melih Tutuncu, Ayse Altintas, Sabahattin Saip
After Fingolimod Discontinuation: Report of Six Cases —Aksel Siva, Ugur Uygunoglu,
Obermann
Tariq Gheith, Rany Aburashed
Corticosteroids for MS Relapse on Blood Pressure: A Pilot Study —Ryan Renn,
P2.093 NMDA Receptor Encephalitis
P2.085 The Prevalence of a History
P2.075 Progressive Multifocal
P2.089 The Effects of High Dose
P2.081 Rebound of Disease Activity
P2.074 Rapid-Onset Immune
Thrombocytopenia Following Alemtuzumab Treatment in Relapsing, Remitting Multiple Sclerosis —Mark
Poster Session 8:30 a.m.–5:30 p.m.
P2.096 Reversal of Relapse Pattern
During Pregnancy in Women Treated with Natalizumab Up to Pregnancy —Charlotte
P2.097 Delayed-Release Dimethyl
Fumarate Does Not Adversely Affect the Pharmacokinetics of a Commonly Used Oral Contraceptive (Norgestimate/Ethinyl Estradiol) in Healthy Women: Drug-Drug Interaction Study Results —Bing Zhu, Karin Galil, Ivan Nestorov, Guolin Zhao, Venkata Meka, Jeanelle Kam, Sarah Sheikh
P2.098 Lymphopenia in Patients with
Multiple Sclerosis Treated with DelayedRelease Dimethyl Fumarate: Analysis of Two United States Electronic Health Record Databases —Madé Wenten, Teesta Soman, Cathy Lally, Maneesh Juneja, Susan Eaton, Claudia Prada, Anne Dilley
P2.099 Characterization of Absolute
Lymphocyte Count Profiles in MS Patients Treated with Delayed-Release Dimethyl Fumarate: Considerations for Patient Management —Robert Fox, Andrew Chan, Ralf Gold, J. Theodore Phillips, Krzysztof Selmaj, Ray Zhang, Ih Chang, Claudia Prada, Catherine Taylor, Jing Marantz
Anemia Associated with Alemtuzumab in a MS Patient with Severe Relapsing Remitting Disease Course and Prior Immune Therapies —Peter Rieckmann,
Arne Lenz, Markus Hoffmann, Udo Poske, Karin Behr, Boris Kallmann
P2.104 Defective Induction of
Tolerogenic Myeloid DCs by IL-27 in Relapsing MS —Felipe Von Glehn Silva,
Gopal Murugaiyan, Keren Regev, Chantal Kuhn, Radhika Raheja, Maria Antonietta Mazzola, Anu Paul, Sushrut Jangi, Pia Kivisakk, Roopali Gandhi, Howard Weiner
P2.105 Role of Family Planning in
Women of Child-Bearing Age with Multiple Sclerosis (MS) in Switzerland: Results of the Women with MS (WWMS) Patient Survey —Sarah Muehl, Stefanie
Mueller, Adam Czaplinski, Petra Stellmes, Christian Kamm
P2.106 Medication Adherence in
Pediatric MS: Barriers and Facilitators —
Stephanie Grover, Kim Edwards, Gulay Alper, Brenda Banwell, Petra Breiner, Mark Gorman, Jennifer Graves, Janace Hart, Timothy Lotze, Soe Mar, Lauren Mednick, Jayne Ness, Austin Noguera, Elizabeth Quon, Teri Schreiner, Carolyn Schwartz, Amy Waldman, Emmanuelle Waubant, Ruth Slater, E. Ann Yeh
P2.107 Clinical Features of CNS-
Autoimmunity After Allogeneic Bone Marrow Transplantation —Felix Bischof, Maria-Ioanna Stefanou
MS and CNS Inflammatory Disease: Treatment Outcome Measures
P2.108 Predicting Treatment Response to Teriflunomide in the TEMSO Study Using the Modified Rio Score —Maria
Pia Sormani, Philippe Truffinet, Karthinathan Thangavelu, Pascal Rufi, Nicola De Stefano
P2.109 Multiple Sclerosis and EDSS: A Walking Scale Standing on No Apparent Legs —Myassar Zarif, Karl Wissemann,
Peter Marcote, Barbara Bumstead, Christina Burke, Lori Fafard, Smitha Thotam, Marijean Buhse, Jacob Sosnoff, Lisa Muratori, Mark Gudesblatt